Search research articles
Contact Us
Filters
Showing results (1-10 of 19) with videos related to
Page
of 2
Sort By:
The Netherlands Journal of Medicine
|
August 25, 2006
Mirizzi's syndrome
M J B Aarts, L G J B Engels
Oncoimmunology
|
November 16, 2020
Immunotherapy as sensitizer for local radiotherapy
Ben G L Vanneste, Evert J Van Limbergen, Ludwig Dubois, et al.
ESMO Open
|
July 12, 2024
Vascular fingerprint tool to identify patients with testicular cancer treated with cisplatin-based chemotherapy at high risk of early cardiovascular events
A T Meuleman, E L D Volders, S Lubberts, et al.
European Journal of Cancer (Oxford, England : 1990)
|
July 16, 2013
Doxorubicin/cyclophosphamide with concurrent versus sequential docetaxel as neoadjuvant treatment in patients with breast cancer
B E P J Vriens, M J B Aarts, B de Vries, et al.
Clinical Epigenetics
|
May 5, 2021
Development of a prognostic risk model for clear cell renal cell carcinoma by systematic evaluation of DNA methylation markers
S C Joosten, S N O Odeh, A Koch, et al.
Breast Cancer Research and Treatment
|
July 5, 2017
Improved survival for sequentially as opposed to concurrently delivered neoadjuvant chemotherapy in non-metastatic breast cancer
B E P J Vriens, I J H Vriens, M J B Aarts, et al.
Journal of the European Academy of Dermatology and Venereology : JEADV
|
September 18, 2021
Survival of stage IV melanoma in Belgium and the Netherlands
K P M Suijkerbuijk, J B A G Haanen, M J Boers-Sonderen, et al.
Quality of Life Research : an International Journal of Quality of Life Aspects of Treatment, Care and Rehabilitation
|
April 20, 2023
Health-state utilities in long-term advanced melanoma survivors comparable with the general population
M D Egeler, L V van de Poll-Franse, R Tissier, et al.
Acta Oncologica (Stockholm, Sweden)
|
September 14, 2020
Health-related quality of life of long-term advanced melanoma survivors treated with anti-CTLA-4 immune checkpoint inhibition compared to matched controls
A H Boekhout, A Rogiers, K Jozwiak, et al.
ESMO Open
|
December 2, 2021
Trends in survival and costs in metastatic melanoma in the era of novel targeted and immunotherapeutic drugs
M G Franken, B Leeneman, M J B Aarts, et al.
Page
of 2
Search research articles
Search
Showing results (1-10 of 19) with videos related to
Sort By:
Page
of 2
The Netherlands Journal of Medicine
|
August 25, 2006
Mirizzi's syndrome
M J B Aarts, L G J B Engels
Oncoimmunology
|
November 16, 2020
Immunotherapy as sensitizer for local radiotherapy
Ben G L Vanneste, Evert J Van Limbergen, Ludwig Dubois, et al.
ESMO Open
|
July 12, 2024
Vascular fingerprint tool to identify patients with testicular cancer treated with cisplatin-based chemotherapy at high risk of early cardiovascular events
A T Meuleman, E L D Volders, S Lubberts, et al.
European Journal of Cancer (Oxford, England : 1990)
|
July 16, 2013
Doxorubicin/cyclophosphamide with concurrent versus sequential docetaxel as neoadjuvant treatment in patients with breast cancer
B E P J Vriens, M J B Aarts, B de Vries, et al.
Clinical Epigenetics
|
May 5, 2021
Development of a prognostic risk model for clear cell renal cell carcinoma by systematic evaluation of DNA methylation markers
S C Joosten, S N O Odeh, A Koch, et al.
Breast Cancer Research and Treatment
|
July 5, 2017
Improved survival for sequentially as opposed to concurrently delivered neoadjuvant chemotherapy in non-metastatic breast cancer
B E P J Vriens, I J H Vriens, M J B Aarts, et al.
Journal of the European Academy of Dermatology and Venereology : JEADV
|
September 18, 2021
Survival of stage IV melanoma in Belgium and the Netherlands
K P M Suijkerbuijk, J B A G Haanen, M J Boers-Sonderen, et al.
Quality of Life Research : an International Journal of Quality of Life Aspects of Treatment, Care and Rehabilitation
|
April 20, 2023
Health-state utilities in long-term advanced melanoma survivors comparable with the general population
M D Egeler, L V van de Poll-Franse, R Tissier, et al.
Acta Oncologica (Stockholm, Sweden)
|
September 14, 2020
Health-related quality of life of long-term advanced melanoma survivors treated with anti-CTLA-4 immune checkpoint inhibition compared to matched controls
A H Boekhout, A Rogiers, K Jozwiak, et al.
ESMO Open
|
December 2, 2021
Trends in survival and costs in metastatic melanoma in the era of novel targeted and immunotherapeutic drugs
M G Franken, B Leeneman, M J B Aarts, et al.
Page
of 2